 The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine FUDR and dexamethasone Dex regional chemotherapy, and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin systemic chemotherapy will increase disease free survival in patients who have undergone liver resection. The patient will be randomized a computer generated decision as in the flip of a coin to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy. 